SCHEMBL434197

SCHEMBL434197

Cc1ccc(-c2cccnc2)s1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2A6 P11509 15/20 0.63
CYP2C19 P33261 10/20 0.63
CYP2C9 P11712 10/20 0.63
CYP3A4 P08684 9/20 0.63
CYP2D6 P10635 8/20 0.63
CYP2E1 P05181 8/20 0.63
CYP2B6 P20813 8/20 0.63
ALDH1A1 P00352 1/20 0.56
CYP1A2 P05177 1/20 0.56
MKNK1 Q9BUB5 1/20 0.56
MKNK2 Q9HBH9 1/20 0.56
HDAC3 O15379 1/20 0.53
HDAC4 P56524 1/20 0.53
HDAC1 Q13547 1/20 0.53
HDAC7 Q8WUI4 1/20 0.53
HDAC2 Q92769 1/20 0.53
HDAC10 Q969S8 1/20 0.53
HDAC11 Q96DB2 1/20 0.53
HDAC8 Q9BY41 1/20 0.53
HDAC6 Q9UBN7 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13515161 0.96 CYP2A6 (0.59) CYP2A6CYP2C19CYP2C9CYP3A4CYP2D6
SCHEMBL19219053 0.93 CYP2A6 (0.56) CYP2A6CYP2C19CYP2C9CYP3A4CYP2D6
SCHEMBL29854440 0.87 CYP2A6 (0.73) CYP2A6CYP2C19CYP2C9CYP3A4CYP2D6
SCHEMBL9200850 0.81 CYP2A6 (0.66) CYP2A6CYP2C19CYP2C9CYP3A4CYP2D6
SCHEMBL12632133 0.79 CYP2A6 (0.58) CYP2A6CYP2C19CYP2C9CYP3A4CYP2D6
SCHEMBL12951370 0.78 MAPT (0.39) CYP2A6CYP2C19CYP2C9CYP3A4CYP2D6
SCHEMBL7253718 0.78 CYP2A6 (0.55) CYP2A6CYP2C19CYP2C9CYP3A4CYP2D6
SCHEMBL147151 0.78 HSD17B1 (0.48) CYP2A6CYP2C19CYP2C9CYP3A4CYP2E1
SCHEMBL13035389 0.78 CYP2A6 (1.00) CYP2A6CYP2C19CYP2C9CYP3A4CYP2D6
SCHEMBL12402387 0.78 CYP2A6 (0.61) CYP2A6CYP2C19CYP2C9CYP3A4CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20190295778-A1 PHOTOELECTRIC CONVERSION ELEMENT, DYE-SENSITIZED SOLAR CELL, METAL COMPLEX DYE, DYE SOLUTION, AND TERPYRIDINE COMPOUND OR ESTERIFIED PRODUCT THEREOF FUJIFILM CORPORATION (JP) 2019-09-26 US disclosed
EP-2203435-B1 6, 11-BRIDGED BIARYL MACROLIDES ENANTA PHARM INC (US) 2018-07-18 EP disclosed
US-20170117099-A1 PHOTOELECTRIC CONVERSION ELEMENT, DYE-SENSITIZED SOLAR CELL, METAL COMPLEX DYE, DYE SOLUTION, AND TERPYRIDINE COMPOUND OR ESTERIFIED PRODUCT THEREOF FUJIFILM CORPORATION (JP) 2017-04-27 US disclosed
US-20170117100-A1 PHOTOELECTRIC CONVERSION ELEMENT, DYE-SENSITIZED SOLAR CELL, METAL COMPLEX DYE, DYE SOLUTION, AND TERPYRIDINE COMPOUND OR ESTERIFIED PRODUCT THEREOF FUJIFILM CORPORATION (JP) 2017-04-27 US disclosed
US-9206173-B2 Heterocyclic compounds for the treatment of stress-related conditions OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2015-12-08 US disclosed
US-9206173-B2 Heterocyclic compounds for the treatment of stress-related conditions OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2015-12-08 US disclosed
EP-2590950-B1 N-CYCLYL-3-(CYCLYLCARBONYLAMINOMETHYL)BENZAMIDE DERIVATIVES AS RHO KINASE INHIBITORS BOEHRINGER INGELHEIM INT (DE) 2014-10-15 EP disclosed
US-20140187780-A1 6,11-BRIDGED BIARYL MACROLIDES ENANTA PHARMACEUTICALS, INC. (US) 2014-07-03 US disclosed
EP-2435046-B1 HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF STRESS-RELATED CONDITIONS OTSUKA PHARMA CO LTD (JP) 2013-09-04 EP disclosed
US-20130165641-A1 6,11-BRIDGED BIARYL MACROLIDES ENANTA PHARMACEUTICALS, INC. (US) 2013-06-27 US disclosed
US-20080119418-A1 C-9 ALKENYLIDINE BRIDGED MACROLIDES ENANTA PHARMACEUTICALS, INC. 2008-05-22 US disclosed
US-7332476-B2 Pyridyl substituted ketolide antibiotics NOVARTIS AG (CH) 2008-02-19 US disclosed
US-7332476-B2 Pyridyl substituted ketolide antibiotics NOVARTIS AG (CH) 2008-02-19 US disclosed
US-20080027012-A1 BRIDGED CARBAMATE MACROLIDES ENANTA PHARMACEUTICALS, INC. 2008-01-31 US disclosed
US-20070244160-A1 6-11 Bicyclic Ketolide Derivatives OR YAT SUN 2007-10-18 US disclosed
US-20070232554-A1 3,6-Bridged 9,12-oxolides ENATA PHARMACEUTICALS, INC. 2007-10-04 US disclosed
US-7273853-B2 6-11 bicyclic ketolide derivatives ENANTA PHARMACEUTICALS, INC. (US) 2007-09-25 US disclosed
WO-2007103456-A2 PIPERAZINE AND PIPERIDINE BIARYL DERIVATIVES TRIMERIS, INC. (US) 2007-09-13 WO disclosed
US-20070105896-A1 4-Substituted imidazoles ASTRAZENECA AB (SE) 2007-05-10 US disclosed
US-20070105896-A1 4-Substituted imidazoles ASTRAZENECA AB (SE) 2007-05-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130165641-A1 6,11-BRIDGED BIARYL MACROLIDES CYP2B6, CYP2D6, ABCB11 CYP2A6 4/4885CYP2C19 10/4885CYP2C9 12/4885
US-20190295778-A1 PHOTOELECTRIC CONVERSION ELEMENT, DYE-SENSITIZED SOLAR CELL, METAL COMPLEX DYE, DYE SOLUTION, AND TERPYRIDINE COMPOUND OR ESTERIFIED PRODUCT THEREOF LEF1, MLLT3, CRY1 CYP2A6 2867/4885CYP2C19 2063/4885CYP2C9 1455/4885
US-20070244160-A1 6-11 Bicyclic Ketolide Derivatives AKR1C2, AKR1C3, AKR1C1 CYP2A6 22/4885CYP2C19 21/4885CYP2C9 11/4885
US-20140187780-A1 6,11-BRIDGED BIARYL MACROLIDES CYP2B6, CYP2D6, ABCB11 CYP2A6 4/4885CYP2C19 10/4885CYP2C9 12/4885
US-20080119418-A1 C-9 ALKENYLIDINE BRIDGED MACROLIDES CYP2C9, CCR9, DPP9 CYP2A6 150/4885CYP2C19 4/4885CYP2C9 1/4885
US-20070232554-A1 3,6-Bridged 9,12-oxolides CYP2C9, CYP2C19, CYP2D6 CYP2A6 11/4885CYP2C19 2/4885CYP2C9 1/4885
US-20170117100-A1 PHOTOELECTRIC CONVERSION ELEMENT, DYE-SENSITIZED SOLAR CELL, METAL COMPLEX DYE, DYE SOLUTION, AND TERPYRIDINE COMPOUND OR ESTERIFIED PRODUCT THEREOF DLK1, CACNA1C, CRY1 CYP2A6 3507/4885CYP2C19 1531/4885CYP2C9 1216/4885
US-20080027012-A1 BRIDGED CARBAMATE MACROLIDES HDAC6, SI, HDAC3 CYP2A6 130/4885CYP2C19 11/4885CYP2C9 9/4885
US-20070105896-A1 4-Substituted imidazoles GRIN2C, GRIN2D, GRIN2A CYP2A6 202/4885CYP2C19 48/4885CYP2C9 285/4885
US-20170117099-A1 PHOTOELECTRIC CONVERSION ELEMENT, DYE-SENSITIZED SOLAR CELL, METAL COMPLEX DYE, DYE SOLUTION, AND TERPYRIDINE COMPOUND OR ESTERIFIED PRODUCT THEREOF LEF1, MLLT3, CRY1 CYP2A6 2867/4885CYP2C19 2063/4885CYP2C9 1455/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.